Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating high-dose Sandostatin LAR alone or in combination with a growth hormone receptor antagonist or a dopamine agonist in acromegaly; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Bromocriptine (bromocriptine)
• CABERGOLINE (CABERGOLINE)
• Sandostatin LAR (octreotide)
• Somavert (pegvisomant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acromegaly | Phase 4 | Status: COMPLETED | Results posted: 2011-02-17